The "Man Controlling Trade" statute outside the FTC's Washington, D.C., headquarters. HIV/AIDS clinics recently submitted comments to the commission about PBMs' business practices.

HIV/AIDS Clinics Tell FTC that PBMs Usurp 340B Discounts for Themselves

Pharmacy benefit managers (PBMs) should be stopped from usurping 340B drug discounts from HIV/AIDS clinics and other safety-net providers, Ryan White Clinics for 340B Access (RWC-340B) told the U.S. Federal Trade Commission (FTC) last week.

RWC-340B asked the commission for protection from PBMs in an April 22 letter. The FTC in late February invited the public to comment on how large, vertically integrated PBMs are affecting drug affordability and access. It did so days after an unexpected 2-2 tie vote doomed Chair Lina Khan’s proposal that the commission investigate PBMs commercial practices. The deadline for comments is May 25. Drug manufacturers and other stakeholders are expected to submit comments as well.

Pharmacy benefit managers (PBMs) should be stopped from usurping 340B drug discounts from HIV/AIDS clinics and other safety-net providers, Ryan White Clinics for 340B Access (RWC-340B) told the U.S. Federal Trade Commission (FTC) last week.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report